376 related articles for article (PubMed ID: 34350378)
21. Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Pan G; Ke S; Zhao J
Target Oncol; 2013 Jun; 8(2):107-16. PubMed ID: 23516098
[TBL] [Abstract][Full Text] [Related]
22. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
23. [Association of taxanes and radiotherapy: preclinical and clinical studies].
Hennequin C
Cancer Radiother; 2004 Nov; 8 Suppl 1():S95-105. PubMed ID: 15679254
[TBL] [Abstract][Full Text] [Related]
24. Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2015 Apr; 15(4):465-75. PubMed ID: 25664933
[TBL] [Abstract][Full Text] [Related]
25. Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results.
Kato T; Seto T; Nishio M; Goto K; Yamamoto N; Okamoto I; Tao L; Yu W; Khaznadar T; Tajima K; Shibata M; Seki A; Yamamoto N
Drug Saf; 2018 Feb; 41(2):229-237. PubMed ID: 29043496
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Qi YT; Hou Y; Qi LC
Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
[TBL] [Abstract][Full Text] [Related]
27. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.
Furness S; Glenny AM; Worthington HV; Pavitt S; Oliver R; Clarkson JE; Macluskey M; Chan KK; Conway DI
Cochrane Database Syst Rev; 2011 Apr; (4):CD006386. PubMed ID: 21491393
[TBL] [Abstract][Full Text] [Related]
28. Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis.
Xiang M; Holsinger FC; Colevas AD; Chen MM; Le QT; Beadle BM
Cancer; 2018 Dec; 124(23):4486-4494. PubMed ID: 30332498
[TBL] [Abstract][Full Text] [Related]
29. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
Zheng L; Wang Y; Xu Z; Yang Q; Zhu G; Liao XY; Chen X; Zhu B; Duan Y; Sun J
Oncologist; 2019 Aug; 24(8):1031-e612. PubMed ID: 31040256
[TBL] [Abstract][Full Text] [Related]
30. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
[TBL] [Abstract][Full Text] [Related]
31. Taxanes in combined-modality therapy for solid tumors.
Choy H
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):23-38. PubMed ID: 10550824
[TBL] [Abstract][Full Text] [Related]
32. The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
Brockstein B; Lacouture M; Agulnik M
J Natl Compr Canc Netw; 2008 Aug; 6(7):696-706. PubMed ID: 18691458
[TBL] [Abstract][Full Text] [Related]
33. Concurrent chemoradiotherapy in non-small cell lung cancer.
Rowell NP; O'rourke NP
Cochrane Database Syst Rev; 2004 Oct; (4):CD002140. PubMed ID: 15495029
[TBL] [Abstract][Full Text] [Related]
34. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.
Furness S; Glenny AM; Worthington HV; Pavitt S; Oliver R; Clarkson JE; Macluskey M; Chan KK; Conway DI;
Cochrane Database Syst Rev; 2010 Sep; (9):CD006386. PubMed ID: 20824847
[TBL] [Abstract][Full Text] [Related]
35. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
Thomas MB; Garrett-Mayer E; Anis M; Anderton K; Bentz T; Edwards A; Brisendine A; Weiss G; Siegel AB; Bendell J; Baron A; Duddalwar V; El-Khoueiry A
Oncology; 2018; 94(6):329-339. PubMed ID: 29719302
[TBL] [Abstract][Full Text] [Related]
36. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.
Yamamoto N; Seto T; Nishio M; Goto K; Yamamoto N; Okamoto I; Yamanaka T; Tanaka M; Takahashi K; Fukuoka M
Lung Cancer; 2021 Jan; 151():20-24. PubMed ID: 33279874
[TBL] [Abstract][Full Text] [Related]
37. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Zibelman M; Mehra R
Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
[TBL] [Abstract][Full Text] [Related]
38. [Radiation therapy and targeted therapies: Risks and opportunities].
Nicolas E; Lucia F
Cancer Radiother; 2022 Oct; 26(6-7):973-978. PubMed ID: 36057520
[TBL] [Abstract][Full Text] [Related]
39. [Chemoradiotherapy of solid tumours in the adult: current views and perspectives].
Noël G; Mazeron JJ; Favaudon V
Bull Cancer; 2003 Jan; 90(1):85-92. PubMed ID: 12609809
[TBL] [Abstract][Full Text] [Related]
40. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
Komaki R; Allen PK; Wei X; Blumenschein GR; Tang X; Lee JJ; Welsh JW; Wistuba II; Liu DD; Hong WK
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):317-24. PubMed ID: 25968826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
